Interview: MedPacto Sees Robust Prospects For ‘Best-In-Class’ ALK5 Inhibitor

MedPacto is preparing for a critical Phase II US study with its potentially best-in-class ALK5 inhibitor, a potential rival to a Lilly molecule and that will be central to the South Korean bioventure’s long-term ambitions to become a global player.